This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Global Blood Therapeutics (GBT) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Global Blood (GBT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Global Blood (GBT) stock based on the movements in the options market lately.
Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options
by Zacks Equity Research
Investors in Global Blood Therapeutics (GBT) need to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options
by Zacks Equity Research
Investors in Global Blood Therapeutics (GBT) need to pay close attention to the stock based on moves in the options market lately.
Why Global Blood Therapeutics (GBT) Could Be Positioned for a Slump
by Zacks Equity Research
It seems to be a wise decision for investors to drop Global Blood Therapeutics (GBT) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.
Company News For Dec 18, 2017
by Zacks Equity Research
Companies In The News are: ADBE,COST,ORCL,GBT
Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options
by Zacks Equity Research
Global Blood Therapeutics (GBT) warrants investors' attention based on moves in the options market lately.
5 Top Performing Stocks of the Best ETF of Q1
by Sweta Killa
Inside the top performing stocks of biotech ETF that tops the list of the best performing ETFs of Q1.
Global Blood Therapeutics (GBT) in Focus: Stock Jumps 6.8%
by Zacks Equity Research
Global Blood Therapeutics, Inc. (GBT) saw its shares rise almost 7% in the last trading session.